BioSpace News Archive

Cambridge Isotope Laboratories, Inc. has acquired an additional 14.8 acres of land at its Cambridge Isotope Separations Xenia, Ohio location.

Diagnosing rare Mendelian disorders is a labor-intensive task, even for experienced geneticists. Investigators at Baylor College of Medicine are trying to make the process more efficient using artificial intelligence.

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after the market close.

Mainz Biomed N.V. announced groundbreaking topline results from a pooled clinical study which included new patients and subjects from Mainz Biomed’s ColoFuture and eAArly DETECT clinical trials evaluating the potential to integrate its portfolio of proprietary novel gene expression biomarkers into a next generation version of the Company’s colorectal cancer screening tool.

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced the award of a contract from HDT Bio for the purpose of rapid, next-generation vaccine development under a ‘Project NextGen: Enabler’ award to HDT Bio.

Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations, it has decided to conduct clinical trials for its ‘niclosamide-based Dengue antiviral’ in Brazil, which has the highest number of dengue cases and deaths in the world.

Exegenesis Bio is pleased to announce the presentation of clinical efficacy and safety data from its EXG001-307 Phase 1/2 clinical trial in Spinal Muscular Atrophy (SMA) Type I at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Baltimore, Maryland on May 8, 2024 (poster #627).

JTC Team (“JTC”), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor “What This Means” segment featuring Moleculin Biotech (NASDAQ:MBRX), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses.

Nexalin Technology, Inc. announced that the Company received notice from The Nasdaq Stock Market on April 23, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550.

Beijing Avistone Biotechnology Co., Ltd. announced the approval to expand the use of vebreltinib from the Chinese National Medical Products Administration for the treatment of adult patients with isocitrate dehydrogenase mutant Astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments.